IL-23A/IL-23 P19 Antibody (tildrakizumab) [Janelia Fluor® 646]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28335JF646
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
ELISA, Flow Cytometry, Functional
Label
Janelia Fluor 646
Antibody Source
Recombinant Monoclonal Human IgG1 Clone # tildrakizumab
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
IL-23a
Clonality
Monoclonal
Host
Human
Isotype
IgG1
Applications for IL-23A/IL-23 P19 Antibody (tildrakizumab) [Janelia Fluor® 646]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: IL-23
Long Name
Interleukin 23
Alternate Names
IL-23 p19/IL-12 p40, IL-23p19/IL-12p40, IL23, SGRF
Gene Symbol
IL23A
Additional IL-23 Products
Product Documents for IL-23A/IL-23 P19 Antibody (tildrakizumab) [Janelia Fluor® 646]
Product Specific Notices for IL-23A/IL-23 P19 Antibody (tildrakizumab) [Janelia Fluor® 646]
Sold under license from the Howard Hughes Medical Institute, Janelia Research Campus.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...